A number of other research analysts also recently issued reports on ADXS. HC Wainwright reiterated a neutral rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, June 12th. Zacks Investment Research raised Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 price objective for the company in a research report on Monday, July 8th.
Shares of NASDAQ:ADXS opened at $1.27 on Thursday. Advaxis has a 12-month low of $1.21 and a 12-month high of $24.60. The firm has a fifty day moving average of $2.15.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Advaxis by 3.1% in the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 43,368 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Advaxis by 5,970.3% in the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 553,031 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Advaxis by 2,468.2% in the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 355,415 shares in the last quarter. 24.40% of the stock is owned by hedge funds and other institutional investors.
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Featured Story: Forex
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.